Anne C. Armstrong

Wilmslow Road
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 69 publications

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 25, 2026

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 26, 2025

Patient-Derived Procoagulant Breast Fibroblasts Expressing Tissue Factor Promote Breast Cancer Cell Migration.

Patient-Derived Procoagulant Breast Fibroblasts Expressing Tissue Factor Promote Breast Cancer Cell Migration.

Journal: Journal of mammary gland biology and neoplasia
Published: November 04, 2025

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.

Journal: ESMO open
Published: October 27, 2025

Immune Checkpoint Inhibitor related Haemophagocytic Lymphohistiocytosis (HLH) in triple negative breast cancer: a case series.

Immune Checkpoint Inhibitor related Haemophagocytic Lymphohistiocytosis (HLH) in triple negative breast cancer: a case series.

Journal: QJM : monthly journal of the Association of Physicians
Published: October 15, 2025

Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis (HLH) in triple negative breast cancer: a case series.

Immune checkpoint inhibitor-related haemophagocytic lymphohistiocytosis (HLH) in triple negative breast cancer: a case series.

Journal: QJM : monthly journal of the Association of Physicians
Published: October 15, 2025

Pregnancy and Breast Cancer: Green-top Guideline No. 12.

Pregnancy and Breast Cancer: Green-top Guideline No. 12.

Journal: BJOG : an international journal of obstetrics and gynaecology
Published: June 17, 2025

Management of menopausal symptoms following treatment for hormone receptor positive breast cancer.

Management of menopausal symptoms following treatment for hormone receptor positive breast cancer.

Journal: The British journal of general practice : the journal of the Royal College of General Practitioners
Published: April 29, 2025

Pregnancy Associated Breast Cancer: An Australian Perspective.

Pregnancy Associated Breast Cancer: An Australian Perspective.

Journal: ANZ journal of surgery
Published: April 25, 2025

Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 04, 2025

To the editor.

To the editor.

Journal: Menopause (New York, N.Y.)
Published: April 03, 2025

Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.

Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.

Journal: Breast cancer research : BCR
Published: March 04, 2025
Showing 1-12 of 69

Last Updated: 09/26/2026